BPC-157: What the Human and Animal Studies Actually Show
Almost all published BPC-157 findings come from animals
BPC-157 is a synthetic peptide promoted online for healing and athletic performance, claims USADA calls unproven [6]. Before asking whether it works, it helps to ask who has been studied. An abstract of a systematic review by Vasireddi and colleagues, hosted in the 2025 American Academy of Orthopaedic Surgeons meeting materials, searched PubMed, Cochrane and Embase and found 544 abstracts. Thirty-nine articles from 1993 to 2024 were included [1].
Of those, the authors describe 13 preclinical musculoskeletal studies (4 muscle, 8 tendon or ligament, 1 fracture), 4 preclinical safety studies and a single human study: a survey of 12 patients who received injections into the knee [1]. The abstract does not give a full animal-versus-human tally for all 39 articles, because some mechanism studies overlap with other categories [1].
The authors report that BPC-157 promoted structural and functional recovery in the animal models and that no adverse effects appeared in animal safety studies. They add that human safety is unknown and that they “caution against the use of BPC-157 by clinicians and athletes” [1].
What animal studies can and cannot tell us
Animal evidence. FDA reviewed the animal literature in a May 2026 briefing document prepared for its compounding advisory committee. The nominators of BPC-157 submitted 25 articles. FDA noted that in rats BPC-157 reduced the size of colonic fistulas by about 40%, reduced NSAID-induced lesions by more than 75% and showed protective effects on the liver [2].
The same review lists limits that matter for people:
- Dose-response relationships for the protective effects “have not been established” [2].
- After injection into a vein, BPC-157’s half-life was about 5.3 minutes in dogs and 15.2 minutes in rats [2].
- In 28-day repeat-dose studies in rats and dogs, FDA saw blood-count and clotting-time changes and liver-related signals, which it said “appeared to be associated with clinically relevant safety signals” [2].
- Tests for genetic damage were negative, and no birth defects were seen in rats. Studies of exposure around and after birth were not done, and FDA found no carcinogenicity studies [2].
- No animal studies were found for several routes nominated for human use, including oral, rectal, subcutaneous and nasal [2].
FDA summarized the safety database as “limited in scope and duration to inform safety considerations” [2]. In other words, animal results are a reason to run careful human trials. They are not evidence that people will benefit or that the substance is safe for them.
The human studies are small, mostly uncontrolled and cover few uses
Human evidence. FDA found five clinical studies in PubMed and Embase [2]:
- 24 healthy volunteers given BPC-157 as an enema for 8 days;
- a randomized, placebo-controlled study in 53 people with ulcerative colitis, available only as a 2005 meeting abstract;
- 17 people given injections into the knee for pain;
- 12 people with interstitial cystitis given an injection into the bladder; and
- 2 healthy volunteers given an intravenous infusion.
FDA also listed an early-phase trial registered as NCT02637284 with no posted results and no publication, and it found no human studies using oral, subcutaneous, nasal or transdermal routes [2].
The ulcerative colitis abstract is the only study in that list that FDA describes as randomized. FDA reported that the average change in a disease activity score was −3.2 with BPC-157 and −1.6 with placebo, but described the methods and endpoints as poorly defined. It concluded that the data “are therefore inadequate to support the efficacy and safety of BPC-157 given as an enema” [2].
The knee-pain study is a useful example of why design matters. Lee and Padgett’s 2021 report was a retrospective chart review at a single clinic, with a phone follow-up and no control group. Of 16 patients reached, 14 said their pain improved, but the outcomes were self-rated, most diagnoses were presumed rather than confirmed by imaging, only 4 patients had an MRI, and the protocol changed partway through [3]. The author lists these as limitations and calls for larger controlled studies [3]. A result like this can suggest an idea worth testing, but it cannot show that the injection caused the improvement.
FDA reviewers found safety gaps beyond the studies themselves
FDA’s briefing raised concerns that go past the thin trial record [2]:
- Immunogenicity. FDA said BPC-157 “may pose a significant risk for immunogenicity, potentially amplified by aggregation,” for injected and nasal routes.
- Impurities. The certificates of analysis FDA reviewed lacked impurity identification and control, and included no endotoxin or bioburden data.
- Adverse event reports. FDA found three reports in its adverse event database, including an injection-site reaction and shortness of breath requiring an emergency visit. It said causality could not be established because of other products and limited detail.
- Long-term use. FDA found no data supporting chronic use.
- Product identity. The nominated substance was unclear (free base versus acetate), and FDA concluded both forms are “not well-characterized.”
On effectiveness, FDA wrote: “There is a lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for UC” [2]. It also noted that several FDA-approved drugs already treat ulcerative colitis [2].
Regulatory and sport status: not approved, and prohibited for athletes
BPC-157 is not FDA-approved. FDA staff recommended against adding it to the list of substances pharmacies can compound, but an advisory committee voted 8–6, with one abstention, to recommend it [4]. In late October 2026, HHS said it would not enforce federal compounding rules against pharmacies that make BPC-157 under set conditions, a move that does not approve the drug [5]. FDA’s own introduction said its evaluation criteria weigh against placing either form of BPC-157 on the list, while noting that its final determination depended on the committee’s input [2]. We explain that policy in our guide to the HHS peptide compounding notice.
For athletes, the U.S. Anti-Doping Agency lists BPC-157 as prohibited under the World Anti-Doping Agency’s S0 category for non-approved substances. USADA states that “there are no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment” and that safe dosing is unknown [6].
What better evidence would look like
FDA’s review points to what is missing. A trial that could answer the question would be randomized and blinded, enroll people with the condition being treated, use one clearly defined product and route, and report prespecified outcomes. FDA found an early-phase trial registered as NCT02637284 whose results were never posted, which shows that even registered work can leave no usable record [2]. Until such trials are published, claims about healing in people rest on animal work and a handful of small reports.
How to read a BPC-157 claim
When you see a claim about BPC-157, four questions help sort the evidence:
- Who was studied? Rats and dogs are not people, and healthy volunteers are not injured patients.
- Was there a control group? Without one, improvement may reflect natural recovery, expectations or other treatments.
- Which route and product? FDA found no human data for most routes in use, and the identity of the product itself was unclear [2].
- Who measured the outcome? Self-reported pain scores after the fact are weaker than blinded, prespecified measures.
By those tests, BPC-157 sits at the low end of our evidence scale. See the BPC-157 profile for its grade, and compare the related TB-500 profile.
Frequently asked questions
Does BPC-157 heal tendons or joints in people?
That has not been shown. The sources we reviewed identify one small, uncontrolled human knee-pain study and no adequately controlled trial of tendon or joint healing [1, 2, 3].
Is BPC-157 safe for humans?
Human safety has not been established. FDA found “insufficient clinical safety information to characterize the safety profile,” and animal toxicity studies showed signals FDA called clinically relevant [2].
Is BPC-157 FDA-approved?
No. FDA reviewers weighed against placing it on the compounding list, and it has no approved use [2, 4].
Is BPC-157 allowed in sport?
No. USADA lists it as prohibited under WADA’s S0 category for non-approved substances [6].
Sources
Every factual claim in this article comes from a source we opened and read while writing it. Where a source is a news or law-firm summary, we say so in the text.
- Vasireddi N, et al. Healing or Hype? Systematic Review of BPC-157 in Orthopedic Sports Medicine Applications (AAOS 2025 abstract)
- FDA briefing document: Evaluation of BPC-157-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List (5/11/2026)
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13
- AJMC: FDA Panel Backs 6 Peptides for Compounding
- Federal Register public inspection: HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Doc. 2026-22192)
- USADA: BPC-157, what athletes should know
Medical disclaimer
Peptides.rodeo is for education only and is not medical advice. Nothing on this site is meant to diagnose, treat, cure or prevent any disease, or to replace a consultation with a licensed physician or pharmacist.
Many compounds described here are not approved by the U.S. Food and Drug Administration for human use. Products sold “for research use only” may be mislabelled, contaminated or of unknown strength. We do not publish dosing protocols for unapproved compounds, and we do not sell, source or recommend vendors.
Evidence grades summarise published research at the date shown and can change as new studies appear. Always talk to a qualified healthcare provider before starting, stopping or changing any medication or supplement, especially if you are pregnant, nursing, have a medical condition or take other medicines. If you think you are having a medical emergency, call 911 or your local emergency number.
Written by Peptides.rodeo Editorial. This article has not been reviewed by a clinician and is not medical advice. We take no money from peptide vendors and use no affiliate links.